Orgotein: a new anti-inflammatory metalloprotein drug: preliminary evaluation of clinical efficacy and safety in degenerative joint disease.
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006621:Hip Joint / Q000187:drug effects; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007270:Injections, Intra-Articular; D007719:Knee Joint / Q000187:drug effects; D008297:Male; D008667:Metalloproteins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D010146:Pain; D014222:Triamcinolone Acetonide / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D008667:Metalloproteins; D014222:Triamcinolone Acetonide; D007213:Indomethacin